Kangstem Biotech Co., Ltd.
Kangstem Biotech promotes a step-by-step business strategy to optimize its success rate of new global medicine development. Kangstem Biotech will create a world where people can enjoy a healthy and happy life by developing stem cell therapeutic products and next generation medicines. Kangstem Biotech strives against incurable diseases to enhance human health by developing advanced bio-pharmaceuticals including stem cell therapies.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
Vision
World’s Top Stem Cell Company
Kangstem Biotech are preparing ‘for the better future than today’ to become the World Top Stem Cell Company respected from customers and markets.
Mission
To give hope for patients with rare and incurable diseases.
Core Value
- Respect for Human Life
- Promotion of Social Welfare
- Creative Innovation
History
We are making the world where everyone can live a healthy and happy life
-
2021
- 07Granted a license for the management of human cells etc.
- 05Approval of IND application for Phase 3 clinical trial of Furestem-AD inj by MFDS
- 04Entered into MOU with Seoul National University Bundang Hospital
- 02Acquisition of cosmetics business
-
2020
- 12Obtained a manufacturing license from MFDS for advanced biopharmaceuticals
- 04Signed MOU for gene and cell therapy research with G+FLAS Life Sciences
-
2019
- 03Signed exclusive rights for domestic sales of Furestem-AD and technology transfer agreement with HYUNDAI Bioland
-
2018
- 02Received IND approval for Phase 1/2a clinical trial of Furestem-RA from MFDS
-
2017
- 09Signed Joint Development Agreement with Germany’s Heraeus Medical GmbH for osteoarthritis stem cell therapy
-
2016
- 10Nominated for Korea-China Science Technology Collaboration Project – Researching stem cell therapy for neurological disorders targeted for Asians
- 10Nominated by The Ministry of Trade, Industry and Energy as a 'K-BrainPower' company
- 02Signed stem cell conditioned media joint business contract with Dongwha Pharmaceutical (MOU)
-
2015
- 12Listed on KOSDAQ
- 08Concluded the contract of iNSC technology joint business with Orig3n of the U.S
- 08Expanded the Construction of Stem Cell GMP Center
- 08Selected for the business in the development of high tech medical technology – Phases 1/2a clinical research for Crohn’ disease
- 07Acquired ISO certificates (ISO 9001, ISO 14001)
- 06Selected for the future industry leading technology development business – R&D for cell culture system
- 01Concluded the joint business contract for the stem cell conditioned medium cosmetics with COSON.
-
2014
- 12Approved of Furestem-CD® Phase 1 (added psoriasis indicant)
- 12Concluded a contract for the stem cell therapy sales right and joint development with Daewoong Pharmaceutical Inc
- 09Selected for the high tech medical technology development business – Occlusive arteriopathy preclinical
- 06Certified for Technology INNO-BIZ
- 05Approved of Furestem-RA® Phase 1
-
2013
- 12Changed business name to Kangstem Biotech
- 10Selected for the parts material business – GvHD preclinical
- 06Approved of Furestem-CD® Phases 1 & 2a
- 01Approved of Furestem-AD® Phases 1 & 2a
-
2012
- 12Selected for the public health medical research development business - Psoriasis preclinical
- 05Selected for the public health medical study development business - Crohn’s disease preclinical
- 02Completed the construction of Stem Cell GMP Center
-
2011
- 12Selected for the industry & academy cooperative technology transfer business – Atopic Dermatitis preclinical
- 08Recognized for the company auxiliary research center by KOITA (Korea Industry & Technology Association)
- 02Certified for the venture company by KIBO (Korea Technology Finance Corporation)
-
2010
- 10Established Kangstem Holdings